Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 07:00 ET | Source: Infex Therapeutics

Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa

Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no...
May 21, 2026 02:00 ET | Source: Infex Therapeutics

Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa

Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no...
May 12, 2026 07:00 ET | Source: Infex Therapeutics

Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections

Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class...
May 12, 2026 02:00 ET | Source: Infex Therapeutics

Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections

Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class...